Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: Two Novel Migraine Drugs Highlight Busy Week For US FDA Approvals

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.

You may also be interested in...



Relief For Migraine as England’s NICE Reverses Ajovy Knockback

The latest decision by the health technology assessment body means up to 10,000 people will be able to receive Teva’s drug on the National Health Service. Ajovy is the first anti-CGRP migraine therapy recommended by NICE, whose decision will also be of interest to CGRP inhibitor rivals including Novartis, Lilly and Lundbeck.

Biohaven’s Oral CGRP Inhibitor Nurtec ODT Approved In The US For Acute Migraine

The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.

Pricing Could Help Lundbeck's Vyepti In Slow-Growing CGRP Market

After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS141768

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel